137 related articles for article (PubMed ID: 30458930)
1. Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers.
Moreno O; Butler T; Zann V; Willson A; Leung P; Connor A
Clin Ther; 2018 Nov; 40(11):1855-1867. PubMed ID: 30458930
[TBL] [Abstract][Full Text] [Related]
2. Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase
Begg M; Edwards CD; Hamblin JN; Pefani E; Wilson R; Gilbert J; Vitulli G; Mallett D; Morrell J; Hingle MI; Uddin S; Ehtesham F; Marotti M; Harrell A; Newman CF; Fernando D; Clark J; Cahn A; Hessel EM
J Pharmacol Exp Ther; 2019 Jun; 369(3):443-453. PubMed ID: 30940692
[TBL] [Abstract][Full Text] [Related]
3. Tolerability, safety, pharmacokinetics and pharmacodynamics of SHR0534, a potent G protein-coupled receptor 40 (GPR40) agonist, at single- and multiple-ascending oral doses in healthy Chinese subjects.
Zhao Y; Xie L; Ou N; Wu J; Zhang H; Zhou S; Liu Y; Chen J; Wang L; Wang L; Wang J; Shao F
Xenobiotica; 2021 Mar; 51(3):297-306. PubMed ID: 33331206
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
Pieniaszek HJ; Sy SK; Ebling W; Fossler MJ; Cain VA; Mondick JT; Ma S; Kornhauser DM
J Clin Pharmacol; 2002 Jul; 42(7):738-53. PubMed ID: 12092741
[TBL] [Abstract][Full Text] [Related]
5. A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson's disease, in healthy volunteers.
Shin W; Lim KS; Kim MK; Kim HS; Hong J; Jhee S; Kim J; Yoo S; Chung YT; Lee JM; Cho DY
Drug Des Devel Ther; 2019; 13():1011-1022. PubMed ID: 30992659
[TBL] [Abstract][Full Text] [Related]
6. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
9. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
[TBL] [Abstract][Full Text] [Related]
10. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects.
Takizawa M; Cerneus D; Michon I; Rijnders S; van der Heide D; Meijer J; Stoelzel M; Sato Y
Adv Ther; 2020 Sep; 37(9):3878-3900. PubMed ID: 32681461
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
Lim KS; Cho JY; Kim BH; Kim JR; Kim HS; Kim DK; Kim SH; Yim HJ; Lee SH; Shin SG; Jang IJ; Yu KS
Br J Clin Pharmacol; 2009 Dec; 68(6):883-90. PubMed ID: 20002082
[TBL] [Abstract][Full Text] [Related]
12. Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models.
Moreno O; Wood J
Target Oncol; 2019 Oct; 14(5):603-611. PubMed ID: 31506873
[TBL] [Abstract][Full Text] [Related]
13. First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects.
Zhou J; Limsakun T; Yin O; Warren V; Zamora C; Atiee G; Kochan J; Pav J; Kobayashi F; Vashi V; Dishy V
J Clin Pharmacol; 2019 Dec; 59(12):1669-1677. PubMed ID: 31243790
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
[TBL] [Abstract][Full Text] [Related]
15. Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib.
Begg M; Wilson R; Hamblin JN; Montembault M; Green J; Deans A; Amour A; Worsley S; Fantom K; Cui Y; Dear G; Ahmad S; Kielkowska A; Clark J; Boyce M; Cahn A; Hessel EM
J Pharmacol Exp Ther; 2019 Jun; 369(3):337-344. PubMed ID: 30886125
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects.
Wilson R; Jarvis E; Montembault M; Hamblin JN; Hessel EM; Cahn A
Clin Ther; 2018 Aug; 40(8):1410-1417. PubMed ID: 30055824
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.
Fujita T; Matsumoto Y; Kimura T; Yokota S; Sawada M; Majima M; Ohtani Y; Kumagai Y
Br J Clin Pharmacol; 2002 Sep; 54(3):283-94. PubMed ID: 12236849
[TBL] [Abstract][Full Text] [Related]
18. Multiple-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral LCB01-0371 in Healthy Male Volunteers.
Cho YS; Lim HS; Cho YL; Nam HS; Bae KS
Clin Ther; 2018 Dec; 40(12):2050-2064. PubMed ID: 30420289
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor.
Mallalieu NL; Rahimy MH; Crowley CA; Appleman JR; Smith PF; Freddo JL
Clin Ther; 2014 Dec; 36(12):2047-2063.e3. PubMed ID: 25456558
[TBL] [Abstract][Full Text] [Related]
20. Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers.
Turncliff R; DiPetrillo L; Silverman B; Ehrich E
Clin Ther; 2015 Feb; 37(2):338-48. PubMed ID: 25456560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
